Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: macrogol 4000; hypromellose; colloidal anhydrous silica; magnesium stearate; propylene glycol; microcrystalline cellulose; lactose monohydrate; purified talc; titanium dioxide; croscarmellose sodium - treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea. note: specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression, in adults, of chronic, recurrent urinary tract infection.

Malta - English - Medicines Authority

fresenius medical care nephrologica deutschland gmbh d-61346 bad homburg, germany - calcium, magnesium - film-coated tablet - calcium 110 mg magnesium 60 mg - mineral supplements

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - ciprofloxacin hydrochloride 291.79mg equivalent to ciprofloxacin 250 mg;   - film coated tablet - 250 mg - active: ciprofloxacin hydrochloride 291.79mg equivalent to ciprofloxacin 250 mg   excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry white oy-s-58910 purified talc purified water   sodium starch glycolate

New Zealand - English - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - ciprofloxacin hydrochloride 875.39mg equivalent to ciprofloxacin 750 mg;   - film coated tablet - 750 mg - active: ciprofloxacin hydrochloride 875.39mg equivalent to ciprofloxacin 750 mg   excipient: colloidal silicon dioxide magnesium stearate maize starch microcrystalline cellulose opadry white oy-s-58910 purified talc purified water   sodium starch glycolate

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - propantheline bromide, quantity: 15 mg - tablet, film coated - excipient ingredients: maize starch; lactose monohydrate; magnesium stearate; purified talc; titanium dioxide; sunset yellow fcf aluminium lake; iron oxide yellow; polyvinyl alcohol; macrogol 3350; lecithin; indigo carmine aluminium lake - this product accepted for registration as 'currently supplied' at the time of commencement of the act. indications were approved as specified in the letter of 7 april 1993 from dr l. hunt are as follows: as an adjunctive therapy in the treatment of peptic ulcer (gastric and duodenal), neurogenic bladder, urinary incontinence in patients with detrusor hyperactivity and hyperhidrosis.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; croscarmellose sodium; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - the treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. the treatment of adults with gastrointestional infections, in particular shigellosis and traveller's diarrhoea. note: specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression in adults of chronic, recurrent urinary tract infections.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - norfloxacin, quantity: 400 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; magnesium stearate; microcrystalline cellulose; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin - treatment of adults with complicated and uncomplicated urinary tract infections that are caused by susceptible strains of microorganisms. treatment of adults with gastrointestinal infections, in particular shigellosis and traveller's diarrhoea. note. specimens for culture and susceptibility testing should be obtained prior to and during treatment if clinical response warrants. suppression in adults of chronic, recurrent urinary tract infection.

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - nitrofurantoin - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - nitrofurantoin - oral tablet - 50mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - nitrofurantoin - oral tablet - 50mg